Mice reconstituted with a human immune system and bearing human tumors represent a promising model for developing novel cancer immunotherapies. Here, we used mass cytometry and multiparametric flow cytometry to characterize human leukocytes infiltrating a human breast cancer tumor model in immunocompromised NOD.SCID.gc-null mice reconstituted with a human immune system and compared it to samples of breast cancer patients. We observed highly activated human CD4 + and CD8 + T cells in the tumor, as well as minor subsets of innate immune cells in both settings. We also report that ICOS + CD4 + regulatory T cells (Treg) were enriched in the tumor relative to the periphery in humanized mice and patients, providing a target to affect Treg and tumor growth. Indeed, administration of a neutralizing mAb to human ICOS reduced Treg proportions and numbers and improved CD4+ T cell proliferation in humanized mice. Moreover, a combination of the anti-ICOS mAb with cyclophosphamide reduced tumor growth, and that was associated with an improved CD8 to Treg ratio. However, depletion of human CD8 + T cells only marginally affected tumor control whereas depletion of murine myeloid cells abrogated the effect of the combination therapy. Altogether, our results indicate that a combination of anti-ICOS mAb and chemotherapy controls tumor growth in humanized mice and highlight the crucial implication of innate immunity in treatment efficacy, opening new perspectives for the treatment of breast cancer.
Introduction
Preventing immune suppression in tumors is the "next frontier" in immuno-oncology research.
Despite recent success of anti-PD-1 mAbs for metastatic melanomas and other solid tumors, it seems reasonable to propose that combination therapy will be key to the success of cancer immunotherapy, as suggested in patients receiving a combination of anti-PD-1 and anti-CTLA-4 (1) . Likely, the most efficient combinations will emerge from the ever growing list of mechanisms that prevent an efficient immune response to the tumor. Recently, a murine study combining a tumor-targeting mAb, a recombinant cytokine, an anti-PD-1 mAb and a T cell vaccine achieved a remarkable efficacy at clearing large established syngeneic tumors (2) , illustrating the power of combinations for T-cell and innate cell mediated tumor control. However, studies purely performed in syngeneic models are only useful to gain biological insights but are not relevant to validate mAbs or drugs selectively targeting human cells. Therefore, a mouse model in which the impact of human-specific mAbs on tumor control could be tested would be most invaluable.
It has been shown that human breast tumor morphology and metastatic properties were conserved in xenografted immunodeficient mice (3, 4) . This was also showed for ovarian cancers (5) and latter confirmed for melanomas (6) , suggesting that a large panel of human tumors engrafts efficiently in immunodeficient mice and reproduces features of clinical progression. Xenograft models might be useful to target human tumors but these immunodeficient models are not relevant to test drugs that target the human immune system, the very definition of immunotherapy. Mice carrying a human immune system (HuMice) and human tumors could therefore represent a relevant model for cancer immunotherapy research, at the interface of mice and humans (7) . Most of the literature regarding the use of HuMice for immuno-oncology relies on direct transfer of total PBMC into immunodeficient mice of various genetic backgrounds. Therapeutic efficacy of a combination of an anti-PD-1 and an anti-4-1-BB mAbs has been demonstrated in a model in which the tumor and the PBMC were from the same patient (8) . However, PBMC-implanted mice invariably and rapidly suffer from Graft vs Host Disease (GVHD), which complicate the interpretation of the results and limits the duration of the experiments. To preclude this problem, NOD.SCID.gamma-c-null (NSG) immunodeficient mice can be reconstituted with human CD34 + hematopoietic progenitors (9) , most often isolated from cord blood.
Because we demonstrated that a pool of human T cells with a diverse repertoire was then generated (10) , it became feasible to assess combination therapy targeting human tumors and/or human T cells in vivo, generating results in a setting closer to human physiology than syngeneic murine models.
However, there is still a lack of information on the composition and the function of human leukocytes infiltrating human tumors in CD34-reconstituted HuMice. Indeed, very few studies have evaluated the nature of human leukocytes in these models (11) (12) (13) (14) (15) . Activated T cells in the tumor were observed in a peculiar model of tumor implantation at birth in NSG HuMice that did not lead to tumor rejection (11) .
A more advanced model of HuMice (MISTRG) was used to decipher the contribution of the innate immune system to tumor control, but the presence of T cells in the tumor was not reported (13) . Very few T cells were detected in a Patient-Derived Xenograft (PDX) HuMice model of head and neck squamous cell carcinomas (14) . Likewise, very few T cells were detected in breast cancer-bearing NSG HuMice with myeloid cells being the subset the most represented in the tumor (12) . Finally, a recent study described the presence of Treg in the tumor of NSG HuMice but a precise quantification of T cells and their associated phenotype was not reported (15) . Thus, the presence of human T cells in tumors of HuMice is still open to debate. This is a crucial question to be answered if one wants to use the model in a reliable and relevant way. To document this question, we used cytometry Time-of-flight (CyTOF) (or mass cytometry) allowing quantification of the expression of 30 to 40 proteins at the same time at the single cell level (18), a very useful feature when analyzing samples containing a limited number of cells. When compared to the immune landscape of breast cancer patients, several conserved features were observed. Among those, the Inducible COStimulatory molecule (ICOS) emerged in both patients and HuMice as an eligible marker to target Tregs, a crucial T cell subset dampening the antitumoral immune response (19) . Here, we provide the first proof-of-principle that a combination of chemotherapy and neutralizing anti-ICOS mAb leads to reduced tumor growth in HuMice, opening the possibility to translate this combination into the clinics.
Results

T cell infiltrate in the tumors of HuMice
The general design of our study is represented on Fig. 1A . Irradiated NSG newborns were injected in the liver with cord blood CD34 + cells. After 16 to 20 weeks, mice were grafted s.c with MDA-MB-231 human breast cancer cells. After 30 to 40 days of tumor growth follow-up, mice were euthanized and the spleen and tumors were analyzed by mass cytometry. The CyTOF panel was designed to include the most common lineage markers for murine and human leukocytes in order to get a global picture of the immune infiltrate, but also incorporated several activation and proliferation markers of human T lymphocytes (Table S1 ).
We first compared the frequencies of human and murine cells of the hematopoietic lineage (CD45 + ) in the spleen and in the tumor in 4 independent experiments, totalizing 15 CD34-reconstituted NSG mice. Within human cells, a classical 2D analysis of the CyTOF data revealed the presence of CD20 + B cells and CD3 + T cells (CD4 + and CD8 + ) in the spleen and the tumor, although B cells tended to disappear from the tumor (Fig. S1A ). To get a deeper insight on the nature of immune cells present in the tumor, we performed unsupervised clustering of the data using the tSNE algorithm. This algorithm reduces the multidimensional nature of mass cytometry data to a 2D representation, in which each dot is a cell, clustered according to the level of expression of chosen markers (16) . We first focused our analysis on manually gated hCD45 + and ran the tSNE algorithm based on lineage and activation markers. Clusters of CD3 + , CD4 + and CD8 + cells were readily detected with that method ( Fig. 1B) . To compare the distribution of human leukocytes in HuMice to human samples, we determined the distribution of human leukocytes in the blood and tumors of 9 breast cancer patients by regular flow cytometry (Fig. 1C ). The mean frequencies of CD3 + T cells were similar in HuMice and patients in the tumor, representing around 50-60% of total CD45 + cells. In contrast, the frequencies of CD4 + T cells were higher and the frequencies of CD8+ T cells were lower in the tumor of HuMice compared to patients. Thus, the MDA-MB-231 cell line was indeed infiltrated by human T cells in CD34-reconstituted HuMice, albeit the ratio of CD4 to CD8 T cells was different.
Innate immune cells in the tumors of HuMice
We next investigated the nature of non-CD19, non-CD3-expressing human cells in the same t-SNE analysis. A distinct cluster of CD33 + HLA-DR + cells was observed in the spleen and tumor of HuMice ( Fig. 2A ). Zooming on CD33 + cells, two distinct populations of CD14 + HLA-DR lo and CD123 + HLA-DR hi cells further segregated, most likely representing monocytes and plasmacytoid dendritic cells (pDCs) precursors, since pDC precursors and mature pDCs differ by CD33 expression To gain information on the murine infiltrate, the same unsupervised representation of the data was performed on gated mCD45 + cells ( Fig. S1B ). As expected from NSG mice, which are deprived of all lymphoid lineages, most mCD45 + cells expressed CD11b in the spleen and the tumor (Fig. S1C ).
Clusters of Ly-6C + monocytes, Ly6-G + neutrophils and CD11c + DC were readily observed in the spleen and the tumor (Fig. S1C ). Overall, myeloid cells of NSG mice were similarly represented in the spleen and the tumor, with the exception of Ly6G + neutrophils which were less abundant in the tumor ( Fig.   S1D ).
Activated/memory T cells in tumors of HuMice
Having established unambiguously that tumors in HuMice contained human T cells, we next investigated the activation status of those cells. We performed a t-SNE analysis on human CD3 + T cells, allowing visualization of two main clusters of CD4 + and CD8 + T cells ( Fig. 3A ). When activation/memory and functional markers such as CD45RO, HLA-DR, PD-1, CD25 or Grz-B were considered, we noticed a general increase in the frequencies of cells positive for those markers in the tumor relative to the spleen for both CD4 + and CD8 + cells, a first indication that T cells were activated in the tumor environment. Up regulation of CD45RO and HLA-DR expression was observed in both CD4 + and CD8 + subsets whereas higher PD-1 and CD25 expression was noted among CD4 + T cells. As expected, up regulation of Grz-B expression was restricted to CD8 + T cells ( Fig. S2A ). To determine the activation status of human T cells more precisely, we performed a boolean analysis calculating the frequencies of cells expressing 0, 1, any combination of 2 or all 3 above mentioned activation markers in CD4 + and CD8 + T cells. Results depicted in Fig. 3B show that the frequencies of CD4 + or CD8 + cells co expressing 2 or 3 activation markers were vastly increased in the tumor, while frequencies of T cells expressing none of the activation markers were drastically reduced. Despite this massive activation, the frequencies of proliferating Ki-67 + cells co-expressing 3 activation markers were lower in tumors relative to the spleen ( Fig. S2B ), although this did not reach statistical significance by a 2-way ANOVA. Importantly, a similar enrichment for activated/memory T cells was observed in the tumor relative to the blood in breast cancer patients, assessed by the co expression of 2 or 3 activation/memory markers ( Fig. 3C ). Thus, tumor infiltrating T cells were of an activated/memory phenotype in both HuMice and breast cancer patients. Of note, PD-1 expression was correlated with higher proliferation of CD4 + and CD8 + T cells in the spleen of HuMice. In contrast, it was inversely correlated with proliferation of CD4 + but surprisingly not of CD8 + T cells in the tumor ( Fig S2C-E) , appearing as an exhaustion marker only for CD4 + T cells.
Increased expression of ICOS on regulatory T cells in tumors
Effector Treg are defined by high expression of the transcription factor FOXP3 and the IL-2Ralpha chain CD25, and by the lack of CD45RA expression (18) . They are important actors of immunosuppression in the tumors of human patients. It has also been shown that ICOS/ICOS-L interaction can regulate Treg functions in humans (19) and that ICOS expression is linked to Tregmediated immunosuppression in breast cancer patients (20, 21) . Furthermore, ICOS expression was associated with poor prognosis in breast cancer patients due to its promoting action on Treg (21, 22) . A distinct cluster of CD4 + cells expressing FOXP3, high levels of ICOS and negative for CD45RA, representing effector Treg was clearly visible in the tumor whereas it was absent in the blood in a patient ( Fig. 4A ). Across many patients, this cluster was represented at higher frequencies in breast tumors compared to blood (Fig. 4B ). It has been shown in humans that CD4 + FOXP3 + CD45RA neg cells might include activated effector T cells with lower FOXP3 expression than effector Treg (18) . We observed that the frequencies of ICOS + cells were higher in FOXP3 hi cells than in FOXP3 lo cells in the tumor ( Fig. 4C ), suggesting that CD4 + CD45RA neg FOXP3 hi ICOS + cells represented bona fide effector Treg. The higher expression of ICOS on Treg of the tumor was also documented by an increase in the MFI of ICOS in FOXP3 + vs. FOXP3 neg cells (Fig. 4D ). Importantly, a similar increase was observed in the tumors of HuMice (Fig. 4D) , showing that over expression of ICOS by Treg in human tumors was recapitulated in HuMice. We thus surmise that ICOS could represent a suitable target to affect Treg, with a possible impact on tumor growth, a testable hypothesis in HuMice.
Impact of anti-ICOS on Treg in HuMice
To test the hypothesis that ICOS/ICOS-L neutralization might affect Treg in vivo, we injected once an anti-hICOS mAb, reported as neutralizing in vitro (21) . 5A ). Moreover, the anti-ICOS mAb treatment was associated with the increased proliferation of total CD4 + but not CD8 + T cells in the spleen (Fig. 5B ). The treatment also affected the absolute numbers of total T cells in the spleen but that did not reach statistical significance. In contrast, Treg counts were significantly reduced by the treatment with numbers dropping almost 20-fold ( Fig. 5C ). Thus, the anti-ICOS mAb led to a significant reduction of FOXP3 + cells in treated animals but also improved proliferation of CD4 + T cells, behaving as an antagonist for Treg and an agonist for conventional T cells.
Combination of chemotherapy and anti-ICOS to control tumor growth in HuMice
To evaluate the impact of the mAb on tumor growth, we dispatched HuMice with similar T cell reconstitution prior the initiation of the experiments (Fig. S3 ) into a pre-clinical-like trial with random assignments into groups, blinded evaluation, mixed sex ratio and sufficient number of animals to detect the observed effect with enough statistical power (the experimental scheme is summarized on Fig. 6A ).
Despite the clear reduction in Treg and CD4 + T cells reported above, the anti-ICOS mAb injected alone at day 7 post-tumor implantation had no effect on tumor growth ( Fig. 6B ). We thus reasoned that combining the anti-ICOS mAb with a known inducer of immunogenic cell death (ICD) might be more efficient, as shown in syngeneic murine models with anti-CTLA-4 or anti-PD-1 mAbs (23) .
Cyclophosphamide (CTX) is widely used as a chemotherapy for treatment of breast cancer for its cytostatic properties, and has also been described as a potent inducer of ICD and may affect Treg as well (24) . Indeed, CTX at a dose of 3 mg per mouse completely abolished tumor growth in nonhumanized NSG mice, whereas a dose of 1.5 mg per mouse only moderately affected tumor growth in non-humanized ( Fig. S4A ) and HuMice alike ( Fig. 6B ), associated to reduced proportions of Treg in treated animals (Fig. S4B ). The combination of the anti-ICOS mAb and CTX injected at day 7 post tumor implantation profoundly reduced tumor growth in HuMice compared to single treatments ( Fig.   6B ). Thus, a combination of CTX with neutralizing anti-ICOS mAb efficiently controlled tumor growth in CD34-reconstituted HuMice. As expected from the results reported above, the proportion of Treg was lower and the CD8 to Treg ratio was higher in the tumor of the combo group relative to CTX alone ( Fig. 6C) , showing that the combined effect of CTX and anti-ICOS was associated to a favorable CD8 to Treg ratio.
Role of human T cells and murine myeloid cells in the control of tumor growth by the combination of chemotherapy and anti-ICOS mAb
Frequencies of human CD45 + CD3 + T cells in the tumor were similar in all groups (Fig. S5 ), indicating that better tumor control in the combo group was not associated to a quantitative increase of human T cells. We thus investigated the role of human CD8 + T cells on tumor control in the combo group. For that, we injected HuMice with a chimeric CD8-depleting recombinant Ig (29) after tumor implantation and before the combination of treatments. As already noted in HuMice (30) , efficient CD8 + T cell depletion was observed in the spleen and tumors of euthanized animals ( Fig. S6A ) that was quantified by a large increase in the CD4 to CD8 ratio ( Fig. S6B ). However, tumor growth was marginally affected by the absence of CD8 + T cells (Fig. 7A) , showing that these were not responsible for better tumor control in the combo group. It was not possible to use a CD4-depleting reagent in HuMice since it would have depleted both Treg and effector CD4 T cells, preventing any conclusions on the sole role of effector CD4 T cells to be drawn. We thus investigated the role of murine myeloid cells on the effect of the combination treatment. We treated a novel set of combo-treated CD34reconstituted HuMice with the anti-Gr1 mAb that deplete Ly6C + and Ly6G + cells, mostly monocytes and neutrophils. Compared to isotype controls, tumors grew better in the anti-Gr1-treated group (Fig.   7B -C), indicating that murine myeloid cells participated in tumor control evoked by the combination of CTX and anti-ICOS mAb.
Discussion
In the present study, we provide the first demonstration that CD34-reconstituted HuMice can be used as a platform for the discovery and the validation of novel combinations of chemotherapy and immunotherapy, potentially applicable to patients. This demonstration originates from several similarities between HuMice and patients that we reveal here using multi parametric fluorescent and mass cytometry. A first similarity that we uncovered here was the composition of the tumor immune landscape. Within total human hematopoietic cells, it is remarkable to note that a similar proportion of CD3 + T cells infiltrated the tumors in patients and in HuMice. Thus, HuMice models might be useful to decipher the molecules and mechanisms at play that attracts T cells within the tumor environment. We also observed similar infiltration of memory/activated CD4 + and CD8 + T cells that expressed a combination of activation markers. However, this activation status did not translate into increased proliferation in the tumor of HuMice, suggesting that the tumor microenvironment of this triple The enrichment for ICOS-expressing Treg is a remarkably conserved feature in HuMice and patients and led us to investigate the therapeutic potential of targeting ICOS for cancer immunotherapy.
ICOS, a member of the Ig superfamily, is an essential co-stimulatory molecule for T cell activation and function. Although originally thought of as a co-stimulatory molecule for effective T helper cell response, the biology of ICOS now extends well beyond this narrowed view (27) . Relevant to the present study, we and others have shown that the survival, the expansion, and the suppressive functions of human Treg were dependent on ICOS signaling (19, 21, 28) . Thus, we evaluated whether an anti-ICOS mAb could affect human Treg in vivo, with possible impact on tumor growth. The reduction in the absolute numbers of total T cells and Treg after anti-ICOS mAb treatment that we report here is in line with an important role for ICOS/ICOS-L on T cells survival. An alternative possibility is that Treg would be physically depleted by the mAb, even though the murine IgG1 isotype used herein is not recognized as a strong inducer of ADCC. This physical depletion is unlikely to occur by complementdependent cytotoxicity since NSG mice, like their NOD relatives, bears a 2-bp deletion in the C5 gene (29) . The murine anti-ICOS mAb might have engaged activating FcRs expressed by myeloid cells, such as FcgRIII, leading to active killing of ICOS-expressing cells, including Treg. Indeed, Treg depletion mediated by myeloid cells has been proposed as a mechanism to explain slower tumor growth following administration of a murine IgG2a isotype to GITR in mice (30) . As put forward in the study of Bulliard et al (30) , much remains to be done to decipher the mechanisms responsible for mAbmediated T cell depletion in mice. Whatever the precise mechanisms that remains to be uncover, Treg depletion is now considered a major mechanism for therapeutic efficacy of anti-CTLA-4 or anti-OX40 mAbs in mice (31) (32) (33) and possibly of Ipilimumab in humans (34) . Additionally, the engagement of ICOS/ICOS-L pathway is required for anti-CTLA-4 efficacy in some models (35) . Several mAbs targeting Treg are in development or already approved, including but not limited to anti-CCR4 (36), anti-OX-40 (37), anti-GITR (38) and anti-CD25 mAb (39) . In addition, the chemokine receptor CCR8 was recently proposed as an attractive target to affect Treg in breast cancer, although this was not directly demonstrated (40) . Our results indicate that ICOS might be a useful addition to this growing list of Treg targets.
In line with published results in murine models (41) , we confirm here that blocking ICOS alone was not sufficient to impact tumor growth. However, a combination of chemotherapy and anti-ICOS mAb significantly impacted tumor growth in CD34-HuMice. This result supports the notion that the reduction in Treg is associated to better tumor control if ICD is simultaneously induced by chemotherapy. However, the results of in vivo depletion experiments did not support an important role for CD8 + T cells on tumor control in the combination group. Thus, we surmise that CD4 + T cells might be central for tumor control following the combined treatment. Multiple modes of action for CD4 + T cells during anti-tumor immunity are possible and remain to be investigated. Given the results of our myeloid cell depletion experiments, we would like to suggest that CD4 + T cells that might have been activated by Treg depletion or directly by the anti-ICOS mAb and that might have attracted murine myeloid cells to the tumor or change their function locally. Supporting this hypothesis, it was recently demonstrated in syngeneic models that combination immunotherapy leads to polarization of monocytes to macrophages (42) . This is also remnant of a comprehensive study showing that the proportion of circulating classical monocytes is a good indicator of successful anti-PD-1 treatment for melanoma (43) . In addition to human CD3 + T cells, our CyTOF analysis showed that the tumors of HuMice also contained rare populations of immune cells known to play important roles during the anti-tumor immune response, such as monocytes or pDCs. The pDC subset that we describe here for the first time in the tumor of HuMice might have played a role on the amplification of ICOS + Treg, as described in breast cancer patients (21) . It will be important in the future to monitor the human myeloid compartment more closely in HuMice models optimized for human myeloid development, since those cells can positively (44) and/or negatively affect the local anti-tumor immune response (45) . We also revealed the presence of NK cells with low expression of NKp46 in the tumor, suggesting impaired function, in agreement with clinical observations (46) .
To our knowledge, our study represents the first demonstration that ICOS represents a target to impact tumor growth in a context of chemotherapy. The presence of ICOS + Treg has been described in breast (20) , ovarian (47) , and gastric (48) carcinomas, melanomas (49, 50) and more recently follicular lymphomas (51), suggesting that ICOS-based cancer immunotherapy might be applicable to a wide range of cancers.
Methods
Mice and humanization NOD.SCID.gc-null mice (stock ≠005557) were originally purchased from the Jackson Laboratory and were bred in our own animal facility under a 14hrs-10hrs light cycle with ad libitum food and water. Mice were given Baytril in their water every other week. Newborns NSG mice were reconstituted by intra hepatic injection of 5. 
Reagents preparation and injection
The 314.8 mAb (mouse IgG1 anti-human ICOS) has been described before (21) . Isotype controls (mouse IgG1, MOPC-1; rat IgG2b, LTF-2) and anti-Gr1 mAb (rat IgG2b, RB6-8C5) were purchased from BioXcell (West Lebanon, NH, USA). The MT807R1 recombinant Ig consisting of rhesus IgG1k constant regions and CDRs derived from the anti-human CD8 antibody M-T807 grafted into rhesus variable framework regions and was provided by the Nonhuman Primate Reagent Resource (NIH contract HHSN272200900037C and grant RR016001). The antibody was expressed in vitro using serum free medium and purified by protein-A affinity chromatography. Endotoxin was <1EU/mg. Cyclophosphamide (CTX, Sigma Aldrich) was prepared extemporaneously according to supplier technical data sheet, i.e to 20 mg/ml of injectable water. All reagents were injected intra peritoneally.
Phenotypic analysis of leukocytes in the spleens and tumors of humanized mice
Splenocytes and tumors were digested with 1.6 mg/ml of collagenase IV and 10 µg/ml of DNAse I (Sigma Aldrich) for 2 hrs at 37° with regular flushing of the tissue. Cells were passed through a 40µm-cell strainer and resuspended in PBS 3% SVF. To eliminate dead cells and debris, tumor cell suspensions were isolated on a Ficoll gradient. Rings were collected, washed and cell pellets were resuspended in PBS 3%SVF before counting with Trypan blue exclusion. Subsequently, 3 to 6. 10 6 cells live cells were stained with corresponding antibodies (lanthanide labeled mAbs for CyTOF or fluorochrome-labeled mAbs for FACS analysis). The details of each panel (each one corresponding to one experiment) can be found in Table S1 . For CyTOF, 1 to 3µl of each lanthanide-labelled mAbs was added in 1.5 ml Eppendorf tubes in a final volume of 50µl of Max Par Staining Buffer (Fluidigm, San Francisco, USA), according to manufacturer protocol. Intracellular staining was performed with FOXP3 staining kit (eBioscience, Courtaboeuf, France). Cell events were acquired on the CyTOF-2 mass cytometer and CyTOF software version 6.0.626 (Fluidigm) at the Cytometry Pitié-Salpétrière core (CyPS). Dual count calibration, noise reduction, cell length threshold between 10 and 150 pushes, and a lower convolution threshold equal to 10 were applied during acquisition. Data files produced by the CyTOF-2 were normalized with the MatLab Compiler software normalizer using the signal from the 4-Element EQ beads (Fluidigm) as recommended by the software developers. Except for the analysis shown in Fig. 1 , GFP exclusion was performed to remove tumor cells from the analysis. To normalize the variability between mice for supervised (i.e 2D plots) and unsupervised (i.e tSNE) analysis, samples from tumors and spleen individually acquired on the CyTOF were aggregated in individual file in each organ and in each experiment.
Clinical samples
The main clinical characteristics of the patients are summarized in Table 1 
Tumor samples from patients and cell isolation
Samples were cut into small fragments, digested with 0.1 mg/ml Liberase TL in the presence of 0.1 mg/ml DNase (Roche, Meylan, France) and incubated for 30 min at 37°C in 5% of CO2 incubator.
Subsequently, cells were filtered on a 40-μm cell strainer (BD Biosciences, Le Pont-de-Claix, France), washed and submitted to staining with specific antibodies. Peripheral blood from breast cancer patients was collected in tubes containing EDTA, washed in PBS and submitted to staining with specific fluorescent-labelled antibodies.
Phenotypic analysis of leukocytes in whole blood and tumors in human breast cancer patients
Tumor cell suspension and whole blood were stained with LIVE/DEAD Fixable Aqua (Life Technologies, Courtaboeuf, France) for 10 min at RT. Then, cells were washed and stained with Aqua The default settings were applied: 1000 iterations, perplexity of 30 and a theta factor of 0.5.
Statistical analysis
Statistical analyses were performed using Prism v6.0h for Mac (GraphPad) with statistical models indicated in the figure legends. Outliers detection method is reported in the figure legends when applicable. All tests were performed with an a of 0.05 (probability of detecting a difference in the means by chance below 5%). No a priori sample size estimation to fit statistical power with the observed effect on tumor growth was used. However, a reverse analysis of our data (G-Power; gpower.hhu.de) showed that given the number of mice included in the study, the observed difference in the means at the end of the experiment and the standard deviations in both groups, the b power was >95%, hence validating the rejection of the null hypothesis by statistical modeling of the data. For statistical analysis of tumor growth, the null hypothesis stating that one curve fits all the data in the compared groups was rejected based if the p-value was inferior to 0.05, determined by nonlinear regression modeling of the data using the exponential growth equation. Results are cumulative of 2 independent experiments (total numbers of mice at the start of the experiment are indicated in brackets). Error bars are SEM. (B) Tumor growth was followed in HuMice treated with the combination of CTX and anti-ICOS mAb and an isotype control (Combo+Iso) or an anti-Gr1 mAb (200µg/mouse i.p). The first injection began 2 days before the combo treatment, followed by 5 injections, twice a week for 3 weeks. In this experiment, NSG female mice were humanized at the age of 3 weeks, then grafted as mentioned with the Luc + MDA breast cancer cell line. 
